News Releases

November 15, 2021
LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
LAVA-051 Phase 1/2a trial actively enrolling in hematological malignancies on track to report initial data in H1 2022 LAVA-1207 Phase 1/2a trial in metastatic castrate resistant prostate cancer on track to begin enrolling later this quarter LAVA-051 granted orphan drug designation by the U.S.
» Full Release
November 11, 2021
LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Symposium
UTRECHT, The Netherlands and PHILADELPHIA and FRAMINGHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage biotechnology company, today announced that LAVA and The Antibody Society , a non-profit association, are co-organizing a virtual symposium
» Full Release
November 9, 2021
LAVA Therapeutics Expands Management Team with Three Key Appointments
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of
» Full Release
November 4, 2021
LAVA Therapeutics to Participate in the 12th Annual Jefferies London Healthcare Conference
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of
» Full Release
November 2, 2021
LAVA Therapeutics Announces Participation at Upcoming Scientific Conferences
Paul W.H.I. Parren, Ph.D., EVP, Head of R&D to share data regarding LAVA bispecific gamma delta T cell engagers derived from proprietary Gammabody™ platform UTRECHT, The Netherlands and PHILADELPHIA, Nov. 02, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.
» Full Release
October 15, 2021
LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia
UTRECHT, The Netherlands and PHILADELPHIA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for the company’s CD1d targeted
» Full Release
October 7, 2021
LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
UTRECHT, The Netherlands and PHILADELPHIA , Oct. 07, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by  LAVA Therapeutics N.V. (Nasdaq: LVTX), please note that in the second paragraph Vγ9Vδ2 T cells were incorrectly written as V9V2 T cells. The corrected release
» Full Release
August 16, 2021
LAVA Therapeutics Provides Business Update and Reports Second Quarter Results
Enrollment continues in Phase 1/2a trial evaluating LAVA-051 in hematological malignancies CTA accepted and IND cleared for Phase 1/2a trial evaluating LAVA-1207 in metastatic castrate resistant prostate cancer; on track to begin later this year Collaboration with Janssen Biotech, Inc.
» Full Release
July 27, 2021
LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary
UTRECHT, The Netherlands and PHILADELPHIA, July 27, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced the appointment of Amy
» Full Release
July 13, 2021
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies
LAVA’s first-in-class gamma-delta bsTCE to be evaluated as a treatment for chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia UTRECHT, The Netherlands and PHILADELPHIA, July 13, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on
» Full Release